DIPG
MCID: DFF037
MIFTS: 45

Diffuse Intrinsic Pontine Glioma (DIPG)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Diffuse Intrinsic Pontine Glioma

MalaCards integrated aliases for Diffuse Intrinsic Pontine Glioma:

Name: Diffuse Intrinsic Pontine Glioma 53 59 73
Dipg 53 59
Infiltrative Brainstem Glioma 53

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA497188
UMLS 73 C2986658

Summaries for Diffuse Intrinsic Pontine Glioma

MalaCards based summary : Diffuse Intrinsic Pontine Glioma, also known as dipg, is related to brain stem glioma and glioma. An important gene associated with Diffuse Intrinsic Pontine Glioma is H3F3A (H3 Histone Family Member 3A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Prednisone and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include brain, pons and eye, and related phenotype is G0/1 arrest.

Wikipedia : 76 A diffuse intrinsic pontine glioma (DIPG) is a tumour located in the pons (middle) of the brain stem. ... more...

Related Diseases for Diffuse Intrinsic Pontine Glioma

Graphical network of the top 20 diseases related to Diffuse Intrinsic Pontine Glioma:



Diseases related to Diffuse Intrinsic Pontine Glioma

Symptoms & Phenotypes for Diffuse Intrinsic Pontine Glioma

GenomeRNAi Phenotypes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 G0/1 arrest GR00098-A-2 9.1 HIST1H3B HIST1H3D HIST1H3E HIST1H3G PARP1 PLK1

Drugs & Therapeutics for Diffuse Intrinsic Pontine Glioma

Drugs for Diffuse Intrinsic Pontine Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
2
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 57-22-7, 2068-78-2 5978
3
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
6
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
7
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
8
Lomustine Approved, Investigational Phase 3,Phase 2 13010-47-4 3950
9
Etoposide Approved Phase 3,Phase 1 33419-42-0 36462
10
Ifosfamide Approved Phase 3 3778-73-2 3690
11
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 4342-03-4 5351166
12
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
13
Valproic Acid Approved, Investigational Phase 3,Phase 2 99-66-1 3121
14
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16
Isophosphamide mustard Phase 3 0
17 Hormone Antagonists Phase 3
18 Antirheumatic Agents Phase 3,Phase 1,Phase 2
19 Nucleic Acid Synthesis Inhibitors Phase 3
20 Antimetabolites Phase 3,Phase 1,Early Phase 1
21 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Early Phase 1
22 Antineoplastic Agents, Hormonal Phase 3
23 Hormones Phase 3
24 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
25 Calcium, Dietary Phase 3
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
27 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Early Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
29 Folic Acid Antagonists Phase 3
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
31 Vitamin B9 Phase 3
32 Alkylating Agents Phase 3,Phase 2,Phase 1,Early Phase 1
33 Vitamin B Complex Phase 3
34 Anti-Inflammatory Agents Phase 3
35 Etoposide phosphate Phase 3,Phase 1
36 Antimitotic Agents Phase 3,Phase 1,Phase 2
37 Folate Phase 3
38 glucocorticoids Phase 3
39 Antimetabolites, Antineoplastic Phase 3,Phase 1,Early Phase 1
40 Dermatologic Agents Phase 3
41 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
42 Anthelmintics Phase 3,Phase 1,Phase 2
43 Chloroquine diphosphate Phase 3 50-63-5
44 Anti-Inflammatory Agents, Non-Steroidal Phase 3
45 Antiprotozoal Agents Phase 3
46 Antiparasitic Agents Phase 3,Phase 1,Phase 2
47 Psychotropic Drugs Phase 3,Phase 2,Phase 1
48 Analgesics Phase 3
49 Neurotransmitter Agents Phase 3,Phase 2
50 Analgesics, Non-Narcotic Phase 3

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
2 Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Unknown status NCT01878266 Phase 3
3 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
4 Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) Completed NCT01182350 Phase 2 Bevacizumab;Erlotinib;Temozolomide
5 Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children Completed NCT01777633 Phase 1, Phase 2
6 Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma Completed NCT00600054 Phase 2
7 Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma Completed NCT00028795 Phase 2 temozolomide
8 A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas Completed NCT00036569 Phase 2
9 Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors Completed NCT01751308 Phase 1, Phase 2 Cabazitaxel (XRP6258)
10 MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma Recruiting NCT03566199 Phase 1, Phase 2 Panobinostat Nanoparticle Formulation MTX110;Convection-Enhanced Delivery (CED)
11 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
12 Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma Recruiting NCT02758366 Phase 2 Doxorubicin
13 REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Recruiting NCT03690869 Phase 1, Phase 2 REGN2810 (monotherapy);REGN2810 (maintenance)
14 A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Recruiting NCT03632317 Phase 2 Panobinostat;Everolimus
15 Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses Recruiting NCT03620032 Phase 2 Nimotuzumab;Vinorelbine
16 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
17 An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies Recruiting NCT03130959 Phase 2
18 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
19 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE 2) Recruiting NCT02343406 Phase 2 Lomustine;ABT-414;Temozolomide
20 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
21 Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01952769 Phase 1, Phase 2
22 A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas Active, not recruiting NCT02750891 Phase 1, Phase 2 DSP-7888
23 Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) Active, not recruiting NCT01469247 Phase 1, Phase 2
24 Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT00879437 Phase 2 Valproic acid;Bevacizumab
25 A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy Active, not recruiting NCT02607124 Phase 1, Phase 2 Ribociclib
26 A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) Active, not recruiting NCT02742883 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
27 Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents Terminated NCT01517776 Phase 2 Cilengitide;Temozolomide
28 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Terminated NCT01836549 Phase 2 imetelstat sodium
29 Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma Completed NCT01400672 Phase 1 Imiquimod
30 PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Completed NCT01393912 Phase 1 Crenolanib
31 Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) Completed NCT00996723 Phase 1 vandetanib and dasatinib
32 Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma Completed NCT01165333 Phase 1 Cilengitide dose escalation;Cilengitide
33 ZD6474 to Treat Advanced Brain Cancer in Patients Completed NCT00272350 Phase 1 Steroids;ZD6474
34 A Phase I Study of SB939 in Pediatric Patients With Refractory Solid Tumours and Leukemia Completed NCT01184274 Phase 1 SB939
35 Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting NCT02420613 Phase 1 Vorinostat;Temsirolimus
36 A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma Recruiting NCT03605550 Phase 1 PTC596
37 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT02717455 Phase 1 LBH589
38 Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Recruiting NCT01922076 Phase 1 Adavosertib
39 Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas Recruiting NCT03696355 Phase 1 GDC-0084
40 CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With DIPG Recruiting NCT03086616 Phase 1 Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
41 Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Recruiting NCT02359565 Phase 1
42 Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Recruiting NCT03178032 Phase 1
43 ONC201 in Pediatric H3 K27M Gliomas Recruiting NCT03416530 Phase 1 ONC201
44 Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Recruiting NCT02644460 Phase 1 Abemaciclib
45 H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas Recruiting NCT02960230 Phase 1
46 Phase I Study of APX005M in Pediatric CNS Tumors Recruiting NCT03389802 Phase 1
47 Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) Recruiting NCT03396575 Phase 1 Cyclophosphamide + Fludarabine Lymphodepletive Conditioning;Dose-Intensified TMZ;Td vaccine
48 Multi-antigen T Cell Infusion Against Neuro-oncologic Disease Recruiting NCT03652545 Phase 1
49 A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG Recruiting NCT03330197 Phase 1 oral veledimex
50 Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Recruiting NCT01502917 Phase 1

Search NIH Clinical Center for Diffuse Intrinsic Pontine Glioma

Genetic Tests for Diffuse Intrinsic Pontine Glioma

Anatomical Context for Diffuse Intrinsic Pontine Glioma

MalaCards organs/tissues related to Diffuse Intrinsic Pontine Glioma:

41
Brain, Pons, Eye, Spinal Cord, Testes, Endothelial, Bone

Publications for Diffuse Intrinsic Pontine Glioma

Articles related to Diffuse Intrinsic Pontine Glioma:

(show top 50) (show all 229)
# Title Authors Year
1
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. ( 29746225 )
2018
2
CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma. ( 29904623 )
2018
3
Corrigendum: Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. ( 29897054 )
2018
4
Correction to: A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. ( 29063425 )
2018
5
IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma. ( 29621254 )
2018
6
The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective. ( 29868485 )
2018
7
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. ( 29914796 )
2018
8
T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity. ( 29151166 )
2018
9
Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma. ( 29207163 )
2018
10
Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma. ( 29484131 )
2018
11
Computation of reliable textural indices from multimodal brain MRI: suggestions based on a study of patients with diffuse intrinsic pontine glioma. ( 29633962 )
2018
12
Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). ( 29484440 )
2018
13
Convection-enhanced delivery: chemosurgery in diffuse intrinsic pontine glioma. ( 29914797 )
2018
14
Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma. ( 29512900 )
2018
15
Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. ( 29967352 )
2018
16
Prospective Feasibility and Safety Assessment of Surgical Biopsy for Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma. ( 29741745 )
2018
17
Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. ( 29954445 )
2018
18
Characterization of Diffuse Intrinsic Pontine Glioma Radiosensitivity using Synchrotron Microbeam Radiotherapy and Conventional Radiation Therapy In Vitro. ( 29364085 )
2018
19
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. ( 29143272 )
2018
20
Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. ( 29755954 )
2018
21
REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. ( 29435175 )
2018
22
End-of-life care of children with diffuse intrinsic pontine glioma. ( 29397521 )
2018
23
Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted Therapeutics. ( 29742880 )
2018
24
Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma. ( 30018882 )
2018
25
Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. ( 30049282 )
2018
26
MELK Inhibition in Diffuse Intrinsic Pontine Glioma. ( 30061363 )
2018
27
Evaluation of 11C-methionine PET and anatomic MRI associations in diffuse intrinsic pontine glioma. ( 30072503 )
2018
28
Bioinformatics analysis of microarray data to reveal the pathogenesis of diffuse intrinsic pontine glioma. ( 30124166 )
2018
29
Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: Implications for development of immunotherapy. ( 30169876 )
2018
30
Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging. ( 30174560 )
2018
31
Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma. ( 30192215 )
2018
32
Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. ( 30206764 )
2018
33
Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity. ( 30254491 )
2018
34
Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG). ( 30340362 )
2018
35
Behavioural changes caused by diffuse intrinsic pontine glioma. ( 30365657 )
2018
36
International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. ( 30446898 )
2018
37
Correction to: International experience in the development of patient-derived xenograft models of diffuse intrinsic pontine glioma. ( 30484110 )
2018
38
Ketogenic diet treatment in recurrent diffuse intrinsic pontine glioma in children: A safety and feasibility study. ( 30484948 )
2018
39
Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma. ( 30544335 )
2018
40
Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases. ( 28780023 )
2018
41
Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients? ( 29198053 )
2018
42
Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients? ( 29667083 )
2018
43
Live-cell single-molecule dynamics of PcG proteins imposed by the DIPG H3.3K27M mutation. ( 29802243 )
2018
44
Effective Drug Delivery in Diffuse Intrinsic Pontine Glioma: A Theoretical Model to Identify Potential Candidates. ( 29164054 )
2017
45
Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. ( 28542253 )
2017
46
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation. ( 28428205 )
2017
47
Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. ( 28947983 )
2017
48
Multiregional tumor drug-uptake imaging by PET and microvascular morphology in end-stage diffuse intrinsic pontine glioma. ( 28818988 )
2017
49
MRI and PET: Noninvasive Tools to Probe the Biology of Diffuse Intrinsic Pontine Glioma. ( 28385794 )
2017
50
Untangling the role of mutant histone H3 in diffuse intrinsic pontine glioma. ( 28388610 )
2017

Variations for Diffuse Intrinsic Pontine Glioma

Expression for Diffuse Intrinsic Pontine Glioma

Search GEO for disease gene expression data for Diffuse Intrinsic Pontine Glioma.

Pathways for Diffuse Intrinsic Pontine Glioma

Pathways related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.2 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
2
Show member pathways
14.01 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
3
Show member pathways
13.91 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
4
Show member pathways
13.91 ACVR1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C
5
Show member pathways
13.86 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
6
Show member pathways
13.85 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
7
Show member pathways
13.84 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
8
Show member pathways
13.63 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
9
Show member pathways
13.61 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
10
Show member pathways
13.58 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
11
Show member pathways
13.52 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
12
Show member pathways
13.43 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
13
Show member pathways
13.43 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
14
Show member pathways
13.27 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
15
Show member pathways
13.16 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
16
Show member pathways
13.12 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
17
Show member pathways
13.11 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
18
Show member pathways
13.03 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
19
Show member pathways
12.89 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
20
Show member pathways
12.5 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
21
Show member pathways
12.49 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
22
Show member pathways
12.42 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
23 12.3 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
24
Show member pathways
12.09 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
25 12 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
26 11.63 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
27 10.77 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F

GO Terms for Diffuse Intrinsic Pontine Glioma

Cellular components related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 nuclear chromosome GO:0000228 9.93 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
2 nuclear nucleosome GO:0000788 9.73 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
3 nuclear chromosome, telomeric region GO:0000784 9.69 H3F3A H3F3B PARP1
4 Barr body GO:0001740 9.48 H3F3A H3F3B
5 nucleosome GO:0000786 9.4 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
6 nucleus GO:0005634 10.36 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
7 membrane GO:0016020 10.34 ACVR1 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E
8 nucleoplasm GO:0005654 10.28 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
9 extracellular region GO:0005576 10.25 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
10 extracellular exosome GO:0070062 10.21 DDAH1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C
11 protein-containing complex GO:0032991 10.2 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
12 chromosome GO:0005694 10.07 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D

Biological processes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 DNA replication-dependent nucleosome assembly GO:0006335 9.96 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
2 interleukin-7-mediated signaling pathway GO:0038111 9.85 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
3 multicellular organism growth GO:0035264 9.75 H3F3A H3F3B MTOR
4 protein heterotetramerization GO:0051290 9.65 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
5 nucleus organization GO:0006997 9.61 H3F3A H3F3B
6 DNA replication-independent nucleosome assembly GO:0006336 9.6 H3F3A H3F3B
7 positive regulation of protein localization to nucleus GO:1900182 9.59 PARP1 PLK1
8 muscle cell differentiation GO:0042692 9.58 H3F3A H3F3B
9 pericentric heterochromatin assembly GO:0031508 9.57 H3F3A H3F3B
10 regulation of centromere complex assembly GO:0090230 9.56 H3F3A H3F3B
11 negative regulation of chromosome condensation GO:1902340 9.55 H3F3A H3F3B
12 telomeric heterochromatin assembly GO:0031509 9.54 H3F3A H3F3B
13 regulation of gene silencing GO:0060968 9.32 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
14 blood coagulation GO:0007596 10.29 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
15 cellular protein metabolic process GO:0044267 10.27 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
16 chromatin silencing at rDNA GO:0000183 10.26 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
17 negative regulation of gene expression, epigenetic GO:0045814 10.23 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
18 chromatin organization GO:0006325 10.22 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
19 nucleosome assembly GO:0006334 10.21 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
20 regulation of gene silencing by miRNA GO:0060964 10.18 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
21 regulation of megakaryocyte differentiation GO:0045652 10.15 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
22 telomere organization GO:0032200 10.1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D

Molecular functions related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.85 HIST1H3A HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F
2 protein heterodimerization activity GO:0046982 9.73 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
3 nucleosomal DNA binding GO:0031492 9.4 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D
4 RNA polymerase II core promoter sequence-specific DNA binding GO:0000979 9.37 H3F3A H3F3B
5 protein binding GO:0005515 10.25 ACVR1 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C
6 DNA binding GO:0003677 10.07 H3F3A H3F3B HIST1H3A HIST1H3B HIST1H3C HIST1H3D

Sources for Diffuse Intrinsic Pontine Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....